Targeting 'sleeper agent' cells in bones of prostate cancer patients
Dormant prostate cancer cells in bone tissue can be reawakened to cause secondary tumours, according to new research published in Endocrine-Related Cancer. Targeting the wake-up call could prevent metastasis and improve prostate cancer survival rates.
Treatment decisions significantly modified by Myriad's prolaris for prostate cancer
Myriad Genetics, Inc. (NASDAQ: MYGN) has announced results from PROCEDE 500, a clinical utility study with its Prolaris test, at the 2014 ASCO Genitourinary Cancers Symposium in San Francisco, Calif. The study demonstrated the significant clinical value of Prolaris to physicians who are treating men with prostate cancer.
New prostate cancer model, known as RapidCaP, reveals a cancer-gene 'switch' that drives metastasis
Prostate cancer is the most common form of cancer in men. Affecting about 1 in 6 men, it is the second deadliest cancer. Research has been stymied by imperfect animal models of the disease, which are costly, take considerable time to develop, and fail to mimic the most lethal aspects of the illness.
Patients receiving androgen deprivation therapy should be counseled to improve mental and emotional well-being
A new study published in The Journal of Urology® reports that prostate cancer patients treated with androgen deprivation therapy (ADT) experienced changes in mental and emotional well-being during treatment, although there was no meaningful decline in emotional quality of life two years after treatment.
New Prostate Cancer drugs may not target root cause of the disease, York scientists warn
New drugs being developed for the treatment of prostate cancer may not be targeting the root cause of the disease, according to research published in Cell Death & Differentiation.Scientists at the University of York have discovered that a process called 'methylation', previously thought to drive the development of cancer, occurs in cells that are already cancerous.
When undergoing androgen deprivation therapy, prostate cancer patients should be counseled to improve mental and emotional well-being
A new study published in the Journal of Urology® reports that prostate cancer patients treated with androgen deprivation therapy (ADT) experienced changes in mental and emotional well-being during treatment, although there was no meaningful decline in emotional quality of life two years after treatment.
Prostate cancer risk may be reduced by melatonin
Higher levels of melatonin, a hormone involved in the sleep-wake cycle, may suggest decreased risk for developing advanced prostate cancer, according to results presented at the AACR-Prostate Cancer Foundation Conference on Advances in Prostate Cancer Research, held Jan. 18-21.
Mechanism affecting risk of prostate cancer is found
A research group at Biocenter Oulu in Finland has identified a mechanism related to a transcription factor that binds much more strongly onto a particular SNP variant, thereby initiating a genetic programme which enhances prostate cancer proliferation and metastasis.
Nomogram aims to enable informed decision-making and personalized treatment for prostate cancer
Studies have found that prostate cancer is overdiagnosed in up to 42 percent of cases, prompting men to receive unnecessary treatment that can cause devastating side effects, including impotence and incontinence.
Pregnancy exposure to BPA in plastic 'raises prostate cancer risk'
A study in mice has found prostate cancer is more likely to develop when exposure to BPA levels matches that typical for pregnant women, according to researchers from the University of Illinois at Chicago (UIC) investigating concerns over the chemical used in water bottles.